PCG
ADVM

Private Capital Group’s Adverum Biotechnologies ADVM Stock Holding History

Private Capital Group’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-50
Closed -$3K – 1962
2019
Q3 		$3K Hold
50
– – ﹤0.01% 1783
2019
Q2 		$3K Hold
50
– – ﹤0.01% 1781
2019
Q1 		$3K Hold
50
– – ﹤0.01% 1777
2018
Q4 		$2K Hold
50
– – ﹤0.01% 1840
2018
Q3 		$3K Hold
50
– – ﹤0.01% 1821
2018
Q2 		$2K Buy
+50
New +$3.01K ﹤0.01% 1867

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
KL
Kam Lawrence $97.4M AUM
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Private Capital Group's ADVM Position: Q4 2019 in Review

Private Capital Group sold out of Adverum Biotechnologies (ADVM) in Q4 2019, closing a stake of 50 shares — an estimated $3K sold.

Private Capital Group first reported a position in ADVM in Q2 2018 and held it in 6 quarters. The position peaked at $3K in Q3 2019. 116 funds tracked by Wall St. Rank hold ADVM as of Q4 2019.

  • Private Capital Group reported no remaining Adverum Biotechnologies position as of Q4 2019 after selling out during the quarter.
  • Private Capital Group sold 50 Adverum Biotechnologies shares in Q4 2019, an estimated $3K.
  • Private Capital Group first reported a position in Adverum Biotechnologies in Q2 2018 and held it in 6 quarters.
  • Private Capital Group's Adverum Biotechnologies position peaked at $3K in Q3 2019.
  • 116 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2019.

Based on Private Capital Group's 13F filing for Q4 2019, filed 14 Feb 2020.